EP1848419B1 - Injectable preparations of diclofenac and its pharmaceutically acceptable salts - Google Patents

Injectable preparations of diclofenac and its pharmaceutically acceptable salts Download PDF

Info

Publication number
EP1848419B1
EP1848419B1 EP06745197A EP06745197A EP1848419B1 EP 1848419 B1 EP1848419 B1 EP 1848419B1 EP 06745197 A EP06745197 A EP 06745197A EP 06745197 A EP06745197 A EP 06745197A EP 1848419 B1 EP1848419 B1 EP 1848419B1
Authority
EP
European Patent Office
Prior art keywords
diclofenac
preparations
high concentration
injectable
injectable preparations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP06745197A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1848419A2 (en
Inventor
Ketan Rajnibhai Aditya 12 Nandihill PATEL
Milan Rajnibhai Aditya 12 Nandihill PATEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Troikaa Pharmaceuticals Ltd
Original Assignee
Troikaa Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36953757&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1848419(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Troikaa Pharmaceuticals Ltd filed Critical Troikaa Pharmaceuticals Ltd
Priority to PL06745197T priority Critical patent/PL1848419T3/pl
Publication of EP1848419A2 publication Critical patent/EP1848419A2/en
Application granted granted Critical
Publication of EP1848419B1 publication Critical patent/EP1848419B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • the present invention relates to high concentration preparations of injectable diclofenac salts that are capable of being administered by intradeltoid route, over and above the intragluteal and slow intravenous route.
  • Diclofenac is used, most commonly, as the Sodium or Potassium salt for relief from pain and inflammation such as Musculoskeletal and joint disorders including rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. It is also useful in peri-articular disorders such as renal colic, acute gout, dysmenorrhea following surgical procedures. It has also been used in some countries for the management of fever.
  • a typical parenteral administration is prepared by suspending or dissolving Sodium / Potassium salt of diclofenac in a non-toxic aqueous or oleaginous medium liquid vehicle.
  • Diclofenac injections have to be administered deep intramuscularly and are generally administered intragluteally as the injection causes substantial pain at the site of injection and its administration in the deltoid (upper arm) region is generally avoided.
  • Pain at the site of injection is due to relatively large volume of the injection (3ml) and the fact that the injection solution contains relatively high volumes of propylene glycol, which is a known irritant upon parenteral administration.
  • the injection solution contains relatively high volumes of propylene glycol, which is a known irritant upon parenteral administration.
  • propylene glycol which is a known irritant upon parenteral administration.
  • injectable diclofenac preparations contain relatively high amounts (18-40%) of propylene glycol, which is a known irritant.
  • propylene glycol which is a known irritant.
  • the Extra Pharmacopoeia 28 th edition, Hand book of excipients further reports that aqueous solution of 2% propylene glycol iso-osmotic with serum causes 100% haemolysis of erythrocytes in 45 min. ( Martindale, the Extrapharmacopoea 28th Editi on)
  • Formulators have attempted to eliminate propylene glycol from the formulation in order to minimize pain at the site of the injection. It must be however be appreciated that the total volume of the injection solution plays a very significant role in addition to the amount of propylene glycol in the cause of pain at the site of the injection. As mentioned above, the volume of the injected solution causes stretching of the muscle fiber, and the higher the volume, more is the damage to the local muscle tissue and hence pain and discomfort at the site of injection..
  • US Patent No.3558690 discloses injectable preparations comprising water soluble salts of substituted phenyl acetic acid derivatives (diclofenac being one such compound) in concentrations of 0.5 to 5 %
  • PCT application number WO 9603121 A1 describes a antiphlogistic, analgesic, antipyretic parenteral preparation comprising diclofenac, its salt, or both, a surfactant, co-surfactant, water, at pH of 3-10 and optionally comprising an oily component, that can exhibit sustained therapeutic levels of diclofenac in plasma and which does not cause pain at site of injection.
  • US Patent 5,554,650 discloses an antiphlogistic, analgesic, antipyretic parenteral preparation that can exhibit sustained therapeutic levels of diclofenac in plasma comprising diclofenac, its salt, or both, a surfactant, co-surfactant, water, adjusted to pH of 3-10 and optionally comprising an oily component.
  • Some preparations claim not to cause pain at site of injection since they exclude propylene glycol and instead use a surfactant and co-surfactant or oil with surfactant and co surfactant to dissolve the diclofenac.
  • European Patent Application number 0658347 A3 describes a method of preparing an injectable pharmaceutical or veterinary composition, which comprises either diclofenac or a salt thereof, and 2 hydroxypropyl betacyclodextrin, or an inclusion complex of diclofenac or a salt thereof and 2 hydorxypropyle betacyclodextrin.
  • Propylene glycol is excluded and solubilisation effected with the help of 2 hydroxypropyl betacyclodextrin.
  • compositions comprising diclofenac as there are CH 694 034 A5 , EP 0 595 766 A1 and EP 085 374 A2 .
  • the present invention attempts to provide preparations of concentrated solutions of water soluble salts of diclofenac and reducing the overall volume of injection to 1ml resulting in the minimization of pain at site of injection. Further, smaller volume enables administration in the deltoid muscle.
  • the main object of the invention is to provide injectable formulations of water-soluble salts of diclofenac, which cause significantly less pain at the site of injection and can be administered by intradeltoid route, in addition to intragluteal and slow intravenous route.
  • Another object of the invention is to provide single doses of less than 2 ml
  • the CH694034 A5 discloses pharmaceutical compositions for parenteral application comprising up to 100mg/ml Diclofenac-potassium in a stabilized aqueous solution at pH 8-8.5.
  • Co-Solvents comprise a mixture of propylene glycol and PEG (e.g. PEG 400).
  • co-solvents / solubilisers such as ⁇ 4 % to 85 % v/v of monohydric alcohol, or ⁇ 27 % to 90 %v/v of polyhydric alcohol, or ⁇ 18 % to 90% v/v of tetrahydrofurfuryl alcohol polyethylene glycol ether (glycofurol), in combination with water as principal solvent allows one to prepare injectables containing 75 mg to 100 mg of water-soluble salts of diclofenac in ⁇ 1 ml injection solution; or, optionally, two or more of these co-solvents/solubilisers used in combination, up to ⁇ 80% v/v monohydric alcohol and/or up to ⁇ 85 % v/v of polyhydric alcohol and/or up to ⁇ 85 % v/v of glycofurol (tetrahydrofurfuryl ), along with water as principal solvent, allows one to prepare injectables containing 75 mg to 100 mg
  • a injectable preparations are prepared as follows:
  • Diclofenac sodium is suspended in a mixture of requisite quantities of glycofurol and say a monohydric alcohol and/or polyhydric alcohol in an inert environment, followed by addition of sterile water for injection, with stirring, followed by addition of a buffer and anti oxidant, then adjusting the pH to 8 - 9 using alkali which on further dilution with sterile water for injection to achieve the required concentration of 75 mg in 1 ml followed by sterilization either by sterile filtration or by autoclaving and filled in 1 ml ampoules flushed with inert gas prior to sealing.
  • the final injectable solution is also filled in 5/10 ml multi dose vials flushed with inert gas prior to sealing.
  • alkali metal salts of the active drug diclofenac diethyl ammonium salts, and the like may also be used.
  • the monohydric alcohols are selected from benzyl alcohol, ethyl alcohol and the like, the polyhydric alcohols being selected from propylene glycol and their like including polyethylene glycols with molecular weight 300 to 600 Dalton, glycerin, 1, 3-butylene glycol.
  • Preferable polyethylene glycols include polyethylene glycol 300, polyethylene glycol 400 and polyethylene glycol 600.
  • the other co-solvent or solubiliser used is glycofurol (tetrahydrofurfuryl alcohol polyethylene glycol ether)
  • Water-soluble salts of diclofenac are used in the range of 7.5% to 10 % w/v.
  • the amount of monohydric alcohol, for example benzyl alcohol, when used as the sole co-solvent / solubiliser, may be incorporated in the range of about 4% to 25% v/v. However when used as co-solvent / solubiliser in combination with other co-solvents the amount of benzyl alcohol is up to about 10 %v/v preferably reduced to about 4% v/v.
  • Polyhydric alcohol such as propylene glycol
  • when used as sole co-solvent/solubiliser maybe incorporated in the range of about 42% to 90% v/v.
  • the amount is up to about 85% v/v.
  • polyethylene glycols for example polyethylene glycol 400
  • amount of polyethylene glycols when used as sole co-solvent is in the range of about 27% to 90% v/v.
  • the amount of tetrahydrofurfuryl alcohol polyethylene glycol ether (glycofurol), when used as sole co-solvent/solubiliser, maybe in the range of about 18 to 90% v/v. However when used as a co-solvent/solubiliser with other co-solvents/solubilisers, the amount is up to about 85% v/v.
  • the antioxidants are selected from sodium bisulphite, sodium meta bisulphite and their like, the alkali is selected form sodium hydroxide, potassium hydroxide and their like, and the buffer system is phosphate buffer, bicarbonate buffer and their like.
  • a parenteral preparation containing diclofenac sodium 7.5% about 25% v/v glycofurol, about 3% v/v benzyl alcohol is prepared in an inert gas environment by suspending the diclofenac sodium in a mixture of requisite quantities of glycofurol and benzyl alcohol. Sterile water is added with constant stirring, followed by addition of phosphate buffer and sodium bisulphite and pH adjusted to 8-9 using sodium hydroxide. The solution is diluted with sterile water to achieve the required concentration of 75mg in lml. The entire process is carried out under inert gas environment. The ingredients may be mixed in any order.
  • the resultant solution is sterilized either by sterile filtration or by autoclaving and filled in 1ml ampoules flushed with inert gas prior to sealing.
  • the resultant solution is also filled in 5/10 ml multi dose vials flushed with inert gas prior to sealing.
  • the viscosity of the dose is 2.64 mPa s measured using Oswald U Tube viscometer.
  • the amount of co-solvents/solubiliser is 0.25 ml of glycofurol and 0.03 ml of benzyl alcohol, totaling to 0.28 ml per injected dose.
  • the viscosity of the conventional 3ml diclofenac injections comprising 75mg of diclofenac sodium, which contain 18 to 40 % propylene glycol, is 2.1 to 5.5 mPa s and the quantity of co-solvent propylene glycol is 0.54ml to 1.4ml per injected dose.
  • the viscosity of the dose is 2.23 mPa s measured using Oswald U Tube viscometer.
  • the amount of co-solvent/solubiliser is 0.01 ml of propylene glycol and 0.22 ml of glycofurol, totaling to 0.23 ml per injected dose.
  • the viscosity of the dose is 2.95 mPa s measured using Oswald U Tube viscometer.
  • the amount of co-solvent/solubiliser is 0.25ml of glycofurol and 0.04 ml of benzyl alcohol, totaling to 0.29 ml per injected dose.
  • the final dosage contains.
  • the viscosity of the does is 1.69 mPa s measured using Oswald U Tube viscometer.
  • the amount of co-solvent/solubiliser is 0.13 ml of glycofurol and 0.04 ml of benzyl alcohol, totaling to 0.17 ml per injected dose.
  • the viscosity of the dose is 1.72 mPa s measured using Oswald U Tube viscometer.
  • the amount of co-solvendsolubiliser is 0.04 ml of benzyl alcohol and 0.13 ml of glycofurol, totaling to 0.17 ml per injected dose.
  • the viscosity of the dose is 1.57 mPa s measured using Oswald U Tube viscometer.
  • the amount of co-solvent/solubiliser is 0.04 ml of benzyl alcohol and 0.05 ml of glycofurol, totaling to 0.09 ml per injected dose.
  • the viscosity of the dose is 1.59 mPa s measured using Oswald U Tube viscometer.
  • the total amount of co-solvent/solubiliser is 0.04ml of benzyl alcohol, 0.02 ml of glycofurol and 0.01 ml of propylene glycol, totaling to 0.07 ml per injected dose.
  • the viscosity of the dose is 3.99 mPa s measured using Oswald U Tube viscometer.
  • the total amount of co-solvent/solubiliser is 0.35ml per injected dose.
  • the viscosity of the dose is 4.38 mPa s measured using Oswald U Tube viscometer.
  • the total amount of co-solvent/solubiliser is 0.45 ml of per injected dose.
  • the viscosity of the dose is 4.69 mPa s measured using Oswald U Tube viscometer.
  • the total amount of co-solvent/solubiliser is 0.35ml per injected dose.
  • Group I consisting of 6 male and 6 female rats was intravenously administered normal saline injections of volume of 0.1 ml / 100g body weight and for the 6 male and 6 female rabbit volume of 0.1 ml/kg body-weight.
  • Group 2 consisting of 6 male and 6 female rats and 6 male and 6 female rabbits was administered 75mg/m Diclofenac sodium equivalent therapeutic intravenously in human dose i.e1.0mg/kg body weight
  • Group 3 consisting of 6 male and 6 female rats and 6 male and 6 female rabbits was administered 75mg/mi Diclofenac sodium equivalent therapeutic intravenously in human dose i.e 5.0 mg/kg body weight
  • Group 4 consisting of 6 male and 6 female rats and 6 male and 6 female rabbits was administered 75mg/ml Diclofenac sodium equivalent therapeutic intravenously in human dose i.e 10.0 mg/kg body weight
  • Serum glucose, serum cholesterol, serum GOT., serum GPT or serum urea levels measured in rats and rabbits were not found to be significantly altered in any of the test groups as compared to control.
  • Serum creatinine was also not altered in any group except in rats treated with 10mg/kg. This dose did not produce any significant change in creatinine levels in rabbits.
  • Histopathological examination of all the organs and the microscopic examination of liver, kidney, lung and heart did not reveal any apparent change except for degenerative changes observed in liver obtained from rabbit treated with 5mg/kg and 10mg/kg diclofenac sodium. The changes in liver have already been reported for diclofenac per se ( Helfgott et al. 1990. JAMA, 264:20 ; Roque et al. 1999. Pharmacol. Experimental Thera, 288: 65-72 .).
  • the adjuvants used in the formulations do not be produce any toxic effect in the animals studied.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
EP06745197A 2005-02-01 2006-01-30 Injectable preparations of diclofenac and its pharmaceutically acceptable salts Active EP1848419B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL06745197T PL1848419T3 (pl) 2005-02-01 2006-01-30 Preparaty diklofenaku i jego farmaceutycznie dopuszczalnych soli do wstrzykiwań

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN96MU2005 2005-02-01
PCT/IN2006/000033 WO2006095363A2 (en) 2005-02-01 2006-01-30 Injectable preparations of diclofenic and its pharmaceutically acceptable salts

Publications (2)

Publication Number Publication Date
EP1848419A2 EP1848419A2 (en) 2007-10-31
EP1848419B1 true EP1848419B1 (en) 2012-07-25

Family

ID=36953757

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06745197A Active EP1848419B1 (en) 2005-02-01 2006-01-30 Injectable preparations of diclofenac and its pharmaceutically acceptable salts

Country Status (20)

Country Link
US (1) US8809393B2 (es)
EP (1) EP1848419B1 (es)
JP (1) JP2008528572A (es)
KR (1) KR101226121B1 (es)
CN (1) CN101123957B (es)
AP (1) AP2888A (es)
AU (2) AU2006221633B2 (es)
BR (1) BRPI0606119B8 (es)
CA (1) CA2596031C (es)
DK (1) DK1848419T3 (es)
EA (1) EA013616B1 (es)
ES (1) ES2392097T3 (es)
IL (1) IL184697A (es)
MX (1) MX2007009312A (es)
NZ (1) NZ554779A (es)
PL (1) PL1848419T3 (es)
PT (1) PT1848419E (es)
UA (1) UA93365C2 (es)
WO (1) WO2006095363A2 (es)
ZA (1) ZA200705729B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009155315A (ja) * 2007-12-26 2009-07-16 Fujiyakuhin Co Ltd 注射剤
WO2013005226A1 (en) * 2011-07-04 2013-01-10 Zota Health Care Ltd A novel combined pharmaceutical composition containing diclofenac and methods of making and using the same
US20140187635A1 (en) * 2012-12-28 2014-07-03 Themis Medicare Limited Diclofenac compositions
US20140275261A1 (en) * 2013-03-15 2014-09-18 Dr. Reddy's Laboratories, Inc. Diclofenac parenteral compositions
CN103432132B (zh) * 2013-08-31 2015-01-21 西南大学 甲磺酸普立地诺双氯芬酸钠注射液及其制备方法
WO2016170401A1 (en) * 2015-04-20 2016-10-27 Umedica Laboratories Pvt. Ltd Novel injectable composition of diclofenac sodium
US20220280463A1 (en) 2019-09-09 2022-09-08 Ftf Pharma Private Limited Pharmaceutical formulations comprising diclofenac

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8200488L (sv) 1982-01-29 1983-07-30 Svenska Flaektfabriken Ab Arreteringsanordning, serskilt for forankring av till- och franluftventiler i ventilationskanaler
DE3328401A1 (de) * 1983-08-05 1985-02-21 Merckle GmbH, 7902 Blaubeuren Injizierbare loesung zur behandlung von entzuendungen
DE3446873A1 (de) * 1984-12-21 1986-07-10 Merckle Gmbh Fluessige diclofenac-zubereitungen
DE3613799C1 (de) * 1986-04-24 1987-09-03 Nattermann A & Cie Verwendung von Glycofurol zum Verfluessigen von Arzneimittelzubereitungen fuer das Abfuellen in Weichgelatinekapseln
WO1991016929A1 (en) * 1990-05-10 1991-11-14 Novo Nordisk A/S A pharmaceutical preparation containing n-glycofurols and n-ethylene glycols
US5389681A (en) * 1992-10-22 1995-02-14 Ciba-Geigy Corporation Parenteral solutions for diclofenac salts
ZA949182B (en) * 1993-12-02 1995-07-26 South African Druggists Ltd Pharmaceutical composition
US5554650A (en) * 1994-07-28 1996-09-10 Southern Research Institute Antiphlogistic, analgesic, antipyretic injection preparation
GB9502695D0 (en) 1995-02-11 1995-03-29 Glaxo Spa Pharmaceutical composition
US5747058A (en) * 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US6544961B1 (en) * 1996-06-25 2003-04-08 Smithkline Beecham Corporation Combinations comprising VX478, zidovudine, FTC and/or 3TC for use in the treatments of HIV
US5853263A (en) * 1996-08-15 1998-12-29 Accrued, Inc. System for installing raised road markers
US6846495B2 (en) * 1999-01-11 2005-01-25 The Procter & Gamble Company Compositions having improved delivery of actives
DE10105576C1 (de) * 2001-02-07 2002-08-08 Underberg Kg Flasche mit im Boden ausgebildeten Griffmulden
IN192711B (es) 2002-01-22 2004-05-15 Ketan Rajnibhai Patel
CH694034A8 (de) * 2002-12-12 2004-08-31 Mepha Ag Diclofenac-Kalium-Injektionsloesung.
EP1605916A4 (en) * 2003-02-12 2012-02-22 R & P Korea Co Ltd SOLUBENT SOLVENT SYSTEM WITH SOLUBLE PEEL WITH IMPROVED ELUTION RATE
KR100612070B1 (ko) * 2003-02-12 2006-08-11 알앤피코리아주식회사 용출률이 향상된 난용성 약제의 용매 시스템 및 이를 함유한 제약학적 제제
CN1557290A (zh) 2004-01-19 2004-12-29 江苏扬子江药业集团有限公司 复方双氯芬酸钾注射液制剂
EP1767219B1 (en) 2004-03-10 2010-01-13 Shimoda Biotech (PTY) LTD Stable injectable diclofenac compositions
CN1279897C (zh) 2004-04-30 2006-10-18 济南百诺医药科技开发有限公司 含有双氯芬酸盐和利多卡因的冻干制剂及其制备方法
ITMI20041245A1 (it) 2004-06-22 2004-09-22 Ibsa Inst Biochimique Sa Composizioni farmaceutiche iniettabnili comprendenti diclofenac sodico e b-ciclodestrina

Also Published As

Publication number Publication date
EP1848419A2 (en) 2007-10-31
DK1848419T3 (da) 2012-11-05
AU2006221633A1 (en) 2006-09-14
BRPI0606119B8 (pt) 2021-05-25
PL1848419T3 (pl) 2012-12-31
BRPI0606119B1 (pt) 2019-05-07
KR101226121B1 (ko) 2013-01-25
WO2006095363B1 (en) 2007-02-01
WO2006095363A2 (en) 2006-09-14
IL184697A0 (en) 2007-12-03
AP2888A (en) 2014-05-31
CA2596031C (en) 2013-02-19
AU2009233594A1 (en) 2009-11-19
AP2007004101A0 (en) 2007-08-31
EA013616B1 (ru) 2010-06-30
WO2006095363A3 (en) 2006-12-14
BRPI0606119A2 (pt) 2009-06-02
JP2008528572A (ja) 2008-07-31
CA2596031A1 (en) 2006-09-14
ZA200705729B (en) 2008-08-27
UA93365C2 (ru) 2011-02-10
US8809393B2 (en) 2014-08-19
IL184697A (en) 2014-02-27
CN101123957A (zh) 2008-02-13
US20080153914A1 (en) 2008-06-26
NZ554779A (en) 2011-02-25
MX2007009312A (es) 2008-03-10
CN101123957B (zh) 2010-12-08
PT1848419E (pt) 2012-10-31
ES2392097T3 (es) 2012-12-04
EA200701645A1 (ru) 2008-02-28
KR20070107091A (ko) 2007-11-06
AU2006221633B2 (en) 2009-07-30

Similar Documents

Publication Publication Date Title
US11179404B2 (en) Formulations of deoxycholic acid and salts thereof
EP1848419B1 (en) Injectable preparations of diclofenac and its pharmaceutically acceptable salts
EP2938325B1 (en) Diclofenac composition
AU2006250765A1 (en) Injectable compositions and process for preparation of such compositions
EP2825039B1 (en) Injectable ibuprofen formulation
ES2843723T3 (es) Formulaciones farmacéuticas inyectables de lefamulina
US9211251B2 (en) Injectable preparations of diclofenac and its pharmaceutically acceptable salts
CA2242364A1 (en) Combination injection preparation
CN1897929A (zh) 包含5－甲基－2－(2′－氯－6′－氟苯胺基)苯乙酸的药物组合物

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070831

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20100119

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602006030957

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A61K0031196000

Ipc: A61K0047100000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/196 20060101ALI20120412BHEP

Ipc: A61K 9/00 20060101ALI20120412BHEP

Ipc: A61K 47/10 20060101AFI20120412BHEP

RTI1 Title (correction)

Free format text: INJECTABLE PREPARATIONS OF DICLOFENAC AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 567430

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120815

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602006030957

Country of ref document: DE

Effective date: 20120920

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20121024

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2392097

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20121204

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

Effective date: 20120725

REG Reference to a national code

Ref country code: PL

Ref legal event code: T3

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20120402405

Country of ref document: GR

Effective date: 20121122

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121125

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120725

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120725

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120725

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120725

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120725

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120725

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20130426

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602006030957

Country of ref document: DE

Effective date: 20130426

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E016378

Country of ref document: HU

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130130

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: RO

Payment date: 20211215

Year of fee payment: 17

Ref country code: SE

Payment date: 20211228

Year of fee payment: 17

Ref country code: CZ

Payment date: 20211222

Year of fee payment: 17

Ref country code: BG

Payment date: 20211229

Year of fee payment: 17

Ref country code: FI

Payment date: 20211222

Year of fee payment: 17

Ref country code: DK

Payment date: 20211222

Year of fee payment: 17

Ref country code: GB

Payment date: 20211228

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20211229

Year of fee payment: 17

Ref country code: CH

Payment date: 20211220

Year of fee payment: 17

Ref country code: BE

Payment date: 20211220

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20211214

Year of fee payment: 17

Ref country code: NL

Payment date: 20211220

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20220126

Year of fee payment: 17

Ref country code: HU

Payment date: 20211219

Year of fee payment: 17

Ref country code: DE

Payment date: 20220112

Year of fee payment: 17

Ref country code: AT

Payment date: 20211222

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20220104

Year of fee payment: 17

Ref country code: PT

Payment date: 20220127

Year of fee payment: 17

Ref country code: IT

Payment date: 20211222

Year of fee payment: 17

Ref country code: FR

Payment date: 20220116

Year of fee payment: 17

Ref country code: ES

Payment date: 20220217

Year of fee payment: 17

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602006030957

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20230131

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20230201

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 567430

Country of ref document: AT

Kind code of ref document: T

Effective date: 20230130

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20230130

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20230131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230131

Ref country code: RO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230130

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230731

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230201

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230131

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230130

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230130

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230801

Ref country code: CZ

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230130

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230131

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230131

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230804

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230131

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230130

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230130

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230131

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20240402

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230131